24 January 2024
Oxford PharmaGenesis has contributed to the development of the new ACCORD reporting guideline to help the medical and scientific communities to improve the reporting of research involving consensus methodologies. The guideline was published in the non-profit open access journal PLOS Medicine.
Together with Pfizer Inc. and Digital Science, Oxford PharmaGenesis colleagues have co-developed an AI-based literature interrogation tool that will help researchers to identify biomarkers of emerging scientific interest in oncology.
Part-funded by Oxford PharmaGenesis, ‘Our Big MS Adventure’ uniquely shows the impact of multiple sclerosis over 12 years, highlighting breakthroughs in treatment, and sharing emotive personal journeys.
Richard White, COO of Oxford PharmaGenesis, provides his expert insights on health economics and outcomes research (HEOR) publications and open access in a new article from the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), the leading global professional society for HEOR.
Share this page Overview Day 1 report Day 2 report Day 3 report Oxford PharmaGenesis at the Virtual 17th Annual Meeting of ISMPP Company overview video ISMPP is a fantastic opportunity to share best practice and connect with people who share our vision for what medical publications and communications can achieve. Chris Winchester, CEO Presentations…
Last week marked the fourth Informatics Summit from the American Medical Informatics Association (AMIA). The meeting provided a fantastic opportunity for members of our Informatics and Data Science practice to stay up to date with the latest developments in the fields of artificial intelligence (AI), natural language processing and machine learning in the context of…
The Friends of the US National Library of Medicine has elected Chris Winchester, CEO of Oxford PharmaGenesis, to its Board of Directors in recognition of the growing collaboration between the two organizations. The move bodes well for the disclosure and dissemination of medical evidence from the pharmaceutical industry and beyond.
